Reuters logo
BRIEF-TG Therapeutics says phase 3 ULTIMATE trials evaluating TG-1101 in multiple sclerosis patients are now open for enrollment
September 15, 2017 / 11:52 AM / 9 days ago

BRIEF-TG Therapeutics says phase 3 ULTIMATE trials evaluating TG-1101 in multiple sclerosis patients are now open for enrollment

Sept 15 (Reuters) - TG Therapeutics Inc

* TG Therapeutics Inc announces the phase 3 ultimate trials evaluating tg-1101 in patients with multiple sclerosis are now open for enrollment

* TG Therapeutics Inc - ‍ ULTIMATE I and ULTIMATE II phase 3 trials will each enroll approximately 440 subjects, randomized in a 1:1 ratio Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below